Clinical trials: Metastatic Renal Cancer
ccRCC, Clear Cell Renal Cell Carcinoma
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
The goal of the Phase 1 portion is to identify the maximum tolerated dose (MTD) and/or the recommended doses for expansion (RDEs) of NKT2152. The Phase 2 portion will evaluate the efficacy of NKT2152 in ccRCC.
- Conditions
- ccRCC, Clear Cell Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasms
- Trial name
- NCT05119335
- Testing
- Oral NKT2152
- Where
- 13 sites in United States
- Volunteers
- 120 people
- Sponsor
- NiKang Therapeutics, Inc.
Cancer
Donor Natural Killer Cell Infusion in Preventing Relapse or Graft Failure in Patients Who Have Undergone Donor Bone Marrow Transplant
RATIONALE: Giving donor natural killer cells to patients who have undergone donor bone marrow transplant may make the transplant work better and keep cancer cells from coming back.
- Trial name
- NCT00569283
- Testing
- therapeutic allogeneic lymphocytes
- Where
- 2 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Asan Medical Center
Renal Cell Carcinoma
Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent
The Sutent® Observational Study is being proposed to assess the real-world usage patterns and effectiveness and tolerability of treatment of Indian patients with advanced renal cell cancer with Sutent®.
- Trial name
- NCT00836745
- Testing
- Non Interventional
- Where
- 7 sites in India
- Volunteers
- 36 people
- Sponsor
- Pfizer
Clear-cell Metastatic Renal Cell Carcinoma
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma: Liquid Biopsy for Biomarkers Discovery
Two randomized trials in the cytokine era clearly showed that cytoreductive nephrectomy (CN) had a role in metastatic renal cell carcinoma (mRCC) increasing life expectancy.
- Trial name
- TARIBO (NCT02535351)
- Testing
- sunitinib or pazopanib, Cytoreductive nephrectomy
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05518253
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Weijia Fang, MD
Metastatic Renal Cell Carcinoma
Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma
This study will evaluate everolimus as second-line therapy in patients with metastatic renal cell carcinoma. Each patient will be enrolled and stratified in one of three cohorts based upon their first-line therapy: 1) prior…
- Trial name
- RECORD-4 (NCT01491672)
- Testing
- RAD001
- Where
- 17 sites in United States, Argentina and 4 more
- Volunteers
- 134 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic or Recurrent Kidney Cancer
This pilot clinical trial studies the side effects and best dose of stereotactic body radiation therapy in treating patients with kidney cancer that has spread to other places in the body (metastatic) or has come back…
- Conditions
- Metastatic Renal Cell Cancer, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Trial name
- NCT02542202
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Chicago
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT01118039
- Testing
- sunitinib malate, immunohistochemistry staining method, laboratory biomarker analysis
- Where
- 4 sites in Spain
- Volunteers
- 41 people
- Sponsor
- Hospital del Mar
Renal Cell Carcinoma, Metastases, Neoplasm
Surgical Treatment of Pancreatic RCC Metastases
Data from 26 patients undergoing resection of Pancreatic Metastases and extra-Pancreatic Metastases from RCC were retrospectively analysed.
- Trial name
- NCT03670992
- Testing
- duodenal-pancreatectomy
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Azienda Policlinico Umberto I
Advanced Solid Tumors
Study of Continuous OSI-906 Dosing
Multicenter, open-label, phase 1, cohort dose escalation study to determine the Maximum Tolerated Dose (MTD) on both Once Daily (QD) and Twice Daily (BID) schedules.
- Trial name
- NCT00514007
- Testing
- OSI-906
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 95 people
- Sponsor
- Astellas Pharma Inc
Locally Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Optimizing Pazopanib Exposure in RCC Patients
Optimization of Pazopanib Exposition in Patients with Renal Cell Carcinoma by Therapeutic Drug Monitoring followed by Individual Dose Escalation.
- Trial name
- OPERA (NCT02089802)
- Testing
- Pazopanib
- Where
- 3 sites in Germany
- Volunteers
- 6 people
- Sponsor
- Interessenverband zur Qualitätssicherung der Arbeit niedergelassener Uro-Onkologen in Deutschland e.
Metastatic Renal Cell Carcinoma
A One-arm Exploratory Clinical Research Program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma Patients.
A one-arm exploratory clinical research program Study of Apatinib in Advanced Metastatic Renal Cell Carcinoma （mRCC） Patients.It's arm to evaluate the treatment of advanced metastatic renal cell carcinoma in patients with…
- Trial name
- NCT02774200
- Testing
- Apatinib
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Kidney Cancer
Sunitinib in Treating Patients With Locally Recurrent or Metastatic Kidney Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00459875
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Adult
Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours
The main purpose of this study is to evaluate the safety and tolerability of EVT801 in subjects with advanced or metastatic solid tumours.
- Trial name
- NCT05114668
- Testing
- EVT801
- Where
- 2 sites in France
- Volunteers
- 32 people
- Sponsor
- Kazia Therapeutics Limited
Cancer
Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer
RATIONALE: Massage therapy may help relieve symptoms associated with cancer. It is not yet known which type of massage therapy is more effective in treating the symptoms of patients with cancer.
- Trial name
- NCT00253708
- Testing
- management of therapy complications, massage therapy, pain therapy
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Beth Israel Deaconess Medical Center
Renal Cell Carcinoma
RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic Therapy for Stage IV Renal Cell Carcinoma
The purpose of this study is to look at the effects of a procedure called radiofrequency ablation on kidney tumors from patients who are undergoing antiangiogenic treatment.
- Trial name
- NCT00601120
- Testing
- Radiofrequency Ablation
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Carcinoma, Renal Cell
A Study of CNTO 328 in Subjects With Metastatic Renal Cell Carcinoma
The purpose of this study is to better understand the safety, tolerability and distribution of CNTO 328 in the bloodstream.
- Trial name
- NCT00265135
- Testing
- CNTO 328
- Where
- 14 sites in Czechia, France and 2 more
- Volunteers
- 68 people
- Sponsor
- Centocor, Inc.
Recurrent/Metastatic Urothelial Cancers
Clinical-pathological Characterization and Outcomes of Metastatic Urothelial Cancer in Latin America
The LACOG 1518 study will characterize demographic and clinical-pathological profile of patients diagnosed with recurrent/ metastatic urothelial cancer in Latin America.
- Trial name
- NCT03942497
- Where
- 9 sites in Brazil
- Volunteers
- 218 people
- Sponsor
- Latin American Cooperative Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00004223
- Testing
- docetaxel, gemcitabine hydrochloride
- Where
- 76 sites in United States, Puerto Rico and 1 more
- Sponsor
- Eastern Cooperative Oncology Group
Metastatic Renal Cell Carcinoma
Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
The purpose of this retrospective observational study was to analyze the effect of targeted therapies administered as second-line treatment after failure of pazopanib as well as increase the amount of information available on…
- Trial name
- SPAZO (NCT02282579)
- Testing
- Pazopanib
- Where
- 34 sites in Spain
- Volunteers
- 300 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.